In a seminal study by Aiello et al., it was found that 36% of patients with proliferative diabetic retinopathy (PDR) did not exhibit elevated VEGF levels in the vitreous body, which explains the unsatisfactory response to anti-VEGF therapy in these individuals [112]. This evidence concerns the gene VEGFA and proliferative diabetic retinopathy.